266 related articles for article (PubMed ID: 18484783)
1. Safety of the nonselective NSAID nabumetone : focus on gastrointestinal tolerability.
Bannwarth B
Drug Saf; 2008; 31(6):485-503. PubMed ID: 18484783
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal safety profile of nabumetone: a meta-analysis.
Huang JQ; Sridhar S; Hunt RH
Am J Med; 1999 Dec; 107(6A):55S-61S; discussion 61S-64S. PubMed ID: 10628594
[TBL] [Abstract][Full Text] [Related]
3. [Gastrointestinal tolerance of nonsteroidal anti-inflammatory agents].
Bannwarth B
Drugs; 2000; 59 Spec No 1():17-23. PubMed ID: 10841069
[TBL] [Abstract][Full Text] [Related]
4. Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases.
Friedel HA; Langtry HD; Buckley MM
Drugs; 1993 Jan; 45(1):131-56. PubMed ID: 7680981
[TBL] [Abstract][Full Text] [Related]
5. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.
Hedner T; Samulesson O; Währborg P; Wadenvik H; Ung KA; Ekbom A
Drugs; 2004; 64(20):2315-43; discussion 2344-5. PubMed ID: 15456329
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety.
Scott DL; Palmer RH
Aliment Pharmacol Ther; 2000 Apr; 14(4):443-52. PubMed ID: 10759624
[TBL] [Abstract][Full Text] [Related]
7. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
[TBL] [Abstract][Full Text] [Related]
8. [Properties and features of nabumetone].
Davies NM; McLachlan AJ
Drugs; 2000; 59 Spec No 1():25-33. PubMed ID: 10841070
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis.
Krug H; Broadwell LK; Berry M; DeLapp R; Palmer RH; Mahowald M
Clin Ther; 2000 Jan; 22(1):40-52. PubMed ID: 10688389
[TBL] [Abstract][Full Text] [Related]
11. Nabumetone: a "nonacidic" nonsteroidal antiinflammatory drug.
Dahl SL
Ann Pharmacother; 1993 Apr; 27(4):456-63. PubMed ID: 8477124
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
Layton D; Souverein PC; Heerdink ER; Shakir SA; Egberts AC
Drug Saf; 2008; 31(2):143-58. PubMed ID: 18217790
[TBL] [Abstract][Full Text] [Related]
13. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
[TBL] [Abstract][Full Text] [Related]
14. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Eversmeyer W; Poland M; DeLapp RE; Jensen CP
Am J Med; 1993 Aug; 95(2A):10S-18S. PubMed ID: 8356997
[TBL] [Abstract][Full Text] [Related]
15. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
Watson DJ; Yu Q; Bolognese JA; Reicin AS; Simon TJ
Curr Med Res Opin; 2004 Oct; 20(10):1539-48. PubMed ID: 15462687
[TBL] [Abstract][Full Text] [Related]
16. Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis.
Simon LS; Zhao SZ; Arguelles LM; Lefkowith JB; Dedhiya SD; Fort JG; Johnson KE
Clin Ther; 1998; 20(6):1218-35; discussion 1192-3. PubMed ID: 9916614
[TBL] [Abstract][Full Text] [Related]
17. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options.
Naesdal J; Brown K
Drug Saf; 2006; 29(2):119-32. PubMed ID: 16454539
[TBL] [Abstract][Full Text] [Related]
18. Review of the cardiovascular safety of COXIBs compared to NSAIDS.
Moodley I
Cardiovasc J Afr; 2008; 19(2):102-7. PubMed ID: 18516356
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Reicin AS; Shapiro D; Sperling RS; Barr E; Yu Q
Am J Cardiol; 2002 Jan; 89(2):204-9. PubMed ID: 11792343
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ
MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
